Illumina, Inc. (ilmn)
ILMN — Company Overview
Illumina, Inc. (ILMN) trades on NMS as part of the Healthcare peer group (Diagnostics & Research).
| Ticker | ILMN |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Exchange | NMS |
| Market cap | $38.56B |
| Last price | $255.38 |
| Size category | Large Cap |
ILMN — Business Description
ILMN represents a Diagnostics & Research business in the Healthcare segment. Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, governmen…
Official website: https://www.illumina.com.
ILMN — Investment Thesis
At a high level, ILMN offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 9.4% year-over-year (public data).
- Trailing P/E of 46.10× implies elevated growth expectations at the current price.
- Equity market capitalization is approximately $38.56B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
ILMN — Financial Health
Key financial health indicators for Illumina, Inc. are derived exclusively from public data — no proprietary estimates.
Profit margin of 18.3% indicates solid bottom-line conversion. Positive free cash flow of $797.63M supports balance-sheet flexibility.
| Trailing P/E | 46.10× |
| Forward P/E | 41.83× |
| Price / Sales | 8.58× |
| Price / Book | 13.59× |
| Gross margin | 67.9% |
| Operating margin | 21.1% |
| Profit margin | 18.3% |
| Return on equity | 32.3% |
| Debt / Equity | 89.04 |
| Free cash flow | $797.63M |
ILMN — Growth Outlook
Growth outlook for Illumina, Inc. (ILMN) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 9.4% suggests steady but measured expansion.
- Earnings declined -9.4% year-over-year — margin or volume pressure may be in play.
- Price is 0.3% below the 52-week high.
ILMN — Competitive Position
Illumina, Inc. (ILMN) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Diagnostics & Research.
- Market capitalization of $38.56B places ILMN among large-cap peers.
- Gross margin near 67.9% may reflect pricing power or favorable mix.
ILMN — Strengths
Strengths for Illumina, Inc. (ILMN) inferred from public financial metrics:
- Revenue growth of 9.4% year-over-year.
- Return on equity near 32.3% — efficient use of shareholder capital.
- Gross margin of 67.9% supports competitive unit economics.
- Positive free cash flow ($797.63M).
- Large Cap scale ($38.56B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
ILMN — Weaknesses
Weaknesses and pressure points for Illumina, Inc. (ILMN) based on available data:
- Earnings decline of -9.4% year-over-year.
- Elevated trailing P/E (46.10×) limits valuation margin of safety.
- High beta (1.47) amplifies market swings.
ILMN — Opportunities
- Sustained revenue growth (9.4%) could support multiple expansion if margins hold.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
ILMN — Risks
- Beta of 1.47 implies above-market volatility.
- Rich valuation (P/E 46.10×) increases downside if growth slows.
ILMN — Summary
Illumina, Inc. (ILMN) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NMS. Last price $255.38 with market cap $38.56B. Trailing P/E 46.10×. Revenue grew 9.4% year-over-year per public data. Notable strengths include revenue growth of 9.4% year-over-year. Key watch items include earnings decline of -9.4% year-over-year. Premium Terminal tools for Illumina, Inc. add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open ILMN in Vest Terminal
Access live data, filings, ownership, and analysis for Illumina, Inc..
Illumina, Inc. FAQ
What does Illumina, Inc. (ILMN) do?
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagent…
What is ILMN's P/E ratio?
Illumina, Inc. has a trailing P/E of 46.10× based on publicly available market data.
Does ILMN pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ILMN in?
Illumina, Inc. is classified in Healthcare (Diagnostics & Research) on NMS.
What is ILMN's market capitalization?
Approximate market cap: $38.56B.
What are the main risks for ILMN?
Key risks include above-average volatility (beta 1.47), elevated valuation, among factors on this page.
What are the strengths of ILMN?
Potential positives include revenue growth of 9.4% year-over-year, return on equity near 32.3% — efficient use of shareholder capital.
Where can I get analyst estimates for ILMN?
Public analyst price targets and consensus for Illumina, Inc. are on the free /stocks/ilmn/estimates page. Deeper estimate history and models are available in Vest Terminal.